Recent Financings of Private Companies (09/2008)
This article was originally published in Start Up
Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
You may also be interested in...
To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.